Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Akebia Therapeutics (AKBA)
NASDAQ:AKBA
Holding AKBA?
Track your performance easily
Earnings Data
Report Date
Mar 12, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.07Last Year’s EPS
$0Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2024
|% Change Since: -8.50%
|Next Earnings Date:Mar 12, 2025
Earnings Call Sentiment|Positive
The earnings call demonstrated strong momentum and strategic positioning for the U.S. launch of Vafseo, with positive engagement from the kidney community and successful reimbursement measures. Despite decreased revenue from Auryxia and an increased net loss, the financial outlook and cash position remain stable.Company Guidance
During the Third Quarter 2024 Earnings Call for Akebia, significant guidance was provided on multiple fronts. The company is preparing for the U.S. market availability of Vafseo (vadadustat) in January 2025, with 60% of dialysis patients already covered under commercial supply contracts. The pricing strategy involves a wholesale acquisition cost of approximately $15,500 per year, with volume-based rebates expected to drive uptake. Akebia secured TDAPA reimbursement from CMS and HCPCS codes to facilitate dialysis organizations' reimbursement submissions. The VOICE trial, set to enroll 2,200 patients, aims to generate data on key endpoints like mortality and hospitalization. Financially, the third quarter saw a total revenue of $37.4 million, with a net loss of $20 million. The company ended the quarter with $34 million in cash and cash equivalents and raised an additional $9.7 million post-Q3. These metrics underscore Akebia's strategic positioning and readiness for Vafseo's market entry.Vafseo U.S. Market Launch Preparation
Significant progress on launch initiatives for Vafseo, including prescriber demand, contracting with dialysis organizations, and clinical initiatives aimed at generating supportive data.
Strong Engagement at ASN Kidney Week
Akebia had a notable presence at ASN Kidney Week, fostering engagement across the kidney community and building awareness for Vafseo. Nephrologists expressed readiness for a new choice in anemia management.
Positive Reimbursement Developments
Secured TDAPA reimbursement from CMS and received HCPCS codes, facilitating Vafseo reimbursement. This supports economics for dialysis organizations, making Vafseo a desirable addition to formularies.
Progress in Dialysis Contracting
Approximately 60% of patients on dialysis have access to Vafseo through contracts with dialysis organizations and group purchasing organizations.
Financial Position and Cash Runway
Ended Q3 with $34 million in cash and cash equivalents, with at least 2 years of cash runway secured.
---
AKBA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
AKBA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $2.00 | $1.86 | -7.00% |
| Aug 08, 2024 | $1.11 | $1.19 | +7.21% |
| May 09, 2024 | $1.40 | $1.33 | -5.00% |
| Mar 14, 2024 | $1.37 | $1.70 | +24.09% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Akebia Therapeutics (AKBA) report earnings?
Akebia Therapeutics (AKBA) is schdueled to report earning on Mar 12, 2025, TBA Not Confirmed.
What is Akebia Therapeutics (AKBA) earnings time?
Akebia Therapeutics (AKBA) earnings time is at Mar 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AKBA EPS forecast?
AKBA EPS forecast for the fiscal quarter 2024 (Q4) is -$0.07.
---